Lonza Posts Higher 2021 Sales; Confirms Mid-Term Targets
By Cecilia Butini
Lonza Group AG on Wednesday posted higher sales for full-year
2021 and reconfirmed its mid-term guidance until 2024.
The Swiss life-sciences company said core earnings before
interest, taxes, depreciation and amortization grew to 1.67 billion
Swiss francs ($1.82 billion), from CHF1.38 billion the year prior,
on sales that grew to CHF5.41 billion from CHF4.51 billion.
Reported Ebitda fell to CHF1.37 billion from CHF1.38 billion
because of a provision the company took for the environmental
remediation of a landfill, it said.
Net profit also declined, coming in at CHF677 million, compared
with CHF732 million in 2020, it said.
The company said it expects low- to mid-teens sales growth at
constant exchange rates in 2022. It also reconfirmed its 2024
mid-term targets, saying that it expects a core Ebitda margin in
line with the mid-term guidance already this year.
Write to Cecilia Butini at email@example.com
(END) Dow Jones Newswires
January 26, 2022 01:50 ET (06:50 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.